major depressive disorder
The new smartphone app, Rejoyn, will deliver treatment to patients taking antidepressant medication aimed at enhancing cognitive control of emotion.
Otsuka intends to invest more than $300 million in an FDA-cleared software app that will apply cognitive therapy principals either with or without prescription drugs.
The past month has seen a succession of publications offering support for Click Therapeutics’ digital offering for patients with major depressive disorder (MDD).